Checkpoint inhibitor - search results

A new type of checkpoint inhibitor, based on glyco-immune chemistry, is being studied to treat bone metastases at Rice University and Baylor College of Medicine.

To help classify patients ahead of checkpoint inhibitor therapy, investigators at UCLA Jonsson Comprehensive Cancer Center have discovered a germline biomarker signature that predicts toxicity to the treatments with 77% accuracy.

The novel approach involves removing tumor cells from the body, treating them with chemotherapy drugs, and then placing them back in the tumor. When delivered along with drugs that activate T cells, these injured cancer cells appear to act as a distress signal that spurs the T cells into action.

Combining CTLA-4 and PD-1 inhibitors produces high responses, yet is often accompanied by immune-related adverse events. The field currently lacks strong biomarkers to understand which patients are most likely to respond to combined checkpoint inhibitors and which are most likely to develop severe toxicity to the treatment.   

Patients who initially may respond well to the checkpoint inhibitors, such as those that target PD-1, can develop resistance to these therapies if their cancer has metastasized from its initial location to form additional tumors in the liver, even if their primary cancer was quite distant from the liver.

Investigators at the Dana-Farber Cancer Institute, in conjunction with researchers at the Broad Institute of MIT and Harvard, have discovered that a metabolic imbalance...

DMAbs may help overcome the roadblocks to targeting checkpoint molecules due to manufacturing complexities and the need for frequent dosing

While the number of patients identified with PDL1 amplifications was small, immune checkpoint blockade was indicated even absent PD-L1 high

The research team focused on natural killer (NK) cells, and developed a monoclonal antibody to block a protein, KIR2DL5, on NK cells.

The biosensors track the activity of protease enzymes, which play a key role in T cell cytotoxicity and tumor biology, and are produced in response to treatment with anti-programmed cell death protein 1 (αPD1) antibodies.